Calcimimetic and calcilytic drugs for treating bone and mineral-related disorders
EF Nemeth, D Shoback - Best Practice & Research Clinical Endocrinology …, 2013 - Elsevier
The calcium-sensing receptor (CaSR) plays a pivotal role in regulating systemic Ca 2+
homeostasis and is a target for drugs designed to treat certain disorders of bone and mineral
metabolism. Calcimimetics are agonists or positive allosteric modulators of the CaSR; they
inhibit parathyroid hormone (PTH) secretion and stimulate renal Ca 2+ excretion. The first
calcimimetic drug is cinacalcet, a positive allosteric modulator of the CaSR that is approved
for treating secondary hyperparathyroidism (HPT) in patients on renal replacement therapy …
homeostasis and is a target for drugs designed to treat certain disorders of bone and mineral
metabolism. Calcimimetics are agonists or positive allosteric modulators of the CaSR; they
inhibit parathyroid hormone (PTH) secretion and stimulate renal Ca 2+ excretion. The first
calcimimetic drug is cinacalcet, a positive allosteric modulator of the CaSR that is approved
for treating secondary hyperparathyroidism (HPT) in patients on renal replacement therapy …